Epitopea secures R&D deal with Merck for tumor-specific antigens
Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called “dark matter” DNA, which are parts of the genome that are thought not to encode for proteins. ...
Epitopea has inked a license and research collaboration with Merck to discover new tumor-specific antigens from so-called “dark matter” DNA, which are parts of the genome that are thought not to encode for proteins. ...
